Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SABS SAB Biotherapeutics
0.670-0.009-1.33%
Trading Session
02/01 14:43 ET
High
0.700
Open
0.690
Turnover
11.54K
Low
0.670
Pre Close
0.679
Volume
16.94K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Reviewing SAB Biotherapeutics (NASDAQ:SABS) and Exelixis (NASDAQ:EXEL)
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the st
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
SAB Biotherapeutics (SABS) Receives a Buy From H.C. Wainwright
SAB Biotherapeutics Gets Additional $8.2M in Funding in Closeout DoD Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Received An Additional $8.2M From DoD Related To Closeout Of The Discontinued COVID-19 Prototype Research And Development Contract
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) shares increased by 59.5% to $3.35 during Wednesday's after-market session. This security traded at a volume of 341.5K shares come close, making up 1423.5% of i
H.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing With
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
SAB Biotherapeutics (NASDAQ:SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D) an
SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,
Company Overview
More
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.
CEO： Dr. Eddie J. Sullivan, PhD
Market： NASDAQ
Listing Date： 02/09/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet